AIDS (London, England) · 2025
Safety and efficacy of immune checkpoint inhibitors in persons with HIV at a single, tertiary care cancer center in the United States.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Graeter Allison, Van Bibber Nathan, Robertson Joshua, Bowles Kristina, Ramaswami Ramya, Lurain Kathryn, Coghill Anna E
Аннотация
BACKGROUND: Immune checkpoint inhibitor (ICI) therapy has demonstrated safety and efficacy in a variety of malignancies, including cancers affecting patients with HIV (PWH). However, there is limited data directly comparing outcomes of ICI use between cancer patients with versus without HIV.
METHODS: Real-world retrospective data were used to compare clinical outcomes between 24 PWH and cancer and 24 matched cancer patients without HIV, all treated with ICI therapy at a large tertiary cancer center in Florida.
RESULTS: Adverse event rates did not differ by HIV status. Overall response (complete or partial response) to ICI therapy was observed in 29% of PWH compared to 38% of people without HIV (PWoH), but this difference was not statistically significant. The overall survival at end of study follow-up by HIV status was similar between both groups (63% in PWH and 67% in PWoH).
CONCLUSION: These findings suggest that HIV status alone should not preclude use of ICI therapy to improve prognosis among PWH and cancer.
METHODS: Real-world retrospective data were used to compare clinical outcomes between 24 PWH and cancer and 24 matched cancer patients without HIV, all treated with ICI therapy at a large tertiary cancer center in Florida.
RESULTS: Adverse event rates did not differ by HIV status. Overall response (complete or partial response) to ICI therapy was observed in 29% of PWH compared to 38% of people without HIV (PWoH), but this difference was not statistically significant. The overall survival at end of study follow-up by HIV status was similar between both groups (63% in PWH and 67% in PWoH).
CONCLUSION: These findings suggest that HIV status alone should not preclude use of ICI therapy to improve prognosis among PWH and cancer.